Please login to the form below
NTDT
This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.
Novartis' Exjade gets EU approval for thalassaemia
Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical
Latest news
-
CHMP backs Novartis' Bexsero, Exjade
It was approved in Europe in March, 2010. Thalassaemia candidate. Meanwhile, the CHMP also gave its backing to Novartis' Exjade (deferasirox) as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, ... Clinical trials have shown
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Roche’s Tamiflu successor hits the mark in complicated flu
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
